uniQure N.V — Quarterly Cash Flow (NASDAQ:QURE) | MetaTrader

Open full chart

Financials

Overview Relevé Statistics

Quarterly Annual

Total assets 556.54 M605.4 M584.89 M888.38 M824.91 M Total liabilities 563.29 M571.72 M588.89 M659.64 M626.01 M Total equity -6.75 M33.69 M-4 M228.75 M198.9 M Total liabilities & shareholders' equities 556.54 M605.4 M584.89 M888.38 M824.91 M Total debt 51.32 M51.59 M51.84 M51.88 M49.7 M Net debt -316.36 M-357.43 M-325.3 M-642.42 M-573.15 M

uniQure N.V

uniQure is a Dutch biopharmaceutical company which makes gene therapies. It has developed several adeno-associated virus gene therapies.

Nouvelles

Nurix Therapeutics (NRIX) Moves 6.9% Higher: Will This Strength Last?

uniQure Investors Sue Company Over Huntington’s Disease Drug Study Claims - TipRanks.com

Biotechs Breathe Easy As Vinay Prasad Plans His Exit. But Should They?

PGIM Jennison Health Sciences Fund Q4 2025 Key Contributors And Detractors

A Unique Situation For UniQure (QURE)

Mizuho relève la note d’uniQure suite au changement à la FDA

Mizuho upgrades uniQure stock rating on FDA leadership change

Les actions de uniQure augmentent de 26% suite à un remaniement de la FDA américaine, même si la dynamique s'effondre : la nouvelle direction approuvera-t-elle la thérapie pour la maladie de Huntington ? | Benzinga France

Avago, Lumentum among market cap stock movers on Monday

Chardan relève l’objectif de cours d’uniQure suite au changement de direction à la FDA

Chardan raises uniQure stock price target on FDA leadership change

Qu'est-ce qui se passe avec Moderna, Capricor et d'autres actions de biotechnologie ce lundi? | Benzinga France